NYSE:RDY - Dr.Reddy's Laboratories Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$36.60 +0.69 (+1.92 %)
(As of 12/13/2018 04:00 PM ET)
Previous Close$35.91
Today's Range$36.06 - $36.78
52-Week Range$28.13 - $39.96
Volume155,800 shs
Average Volume356,922 shs
Market Capitalization$6.18 billion
P/E Ratio36.24
Dividend Yield0.73%
Beta0.13
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. It also provides a portfolio of in-licensed dermatology products. As of March 31, 2018, this segment had 13 active products development programs pipeline that are in various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, pain management, oncology, dermatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; and collaboration agreement with Merck Serono to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.

Receive RDY News and Ratings via Email

Sign-up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:RDY
Previous Symbol
CUSIPN/A
Phone91-40-4900-2900

Debt

Debt-to-Equity Ratio0.21
Current Ratio1.62
Quick Ratio1.17

Price-To-Earnings

Trailing P/E Ratio36.24
Forward P/E Ratio25.77
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.20 billion
Price / Sales2.76
Cash Flow$2.0573 per share
Price / Cash Flow17.79
Book Value$11.71 per share
Price / Book3.13

Profitability

EPS (Most Recent Fiscal Year)$1.01
Net Income$151 million
Net Margins10.62%
Return on Equity13.14%
Return on Assets7.34%

Miscellaneous

Employees23,524
Outstanding Shares166,040,000
Market Cap$6.18 billion
OptionableOptionable

Dr.Reddy's Laboratories (NYSE:RDY) Frequently Asked Questions

What is Dr.Reddy's Laboratories' stock symbol?

Dr.Reddy's Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "RDY."

How were Dr.Reddy's Laboratories' earnings last quarter?

Dr.Reddy's Laboratories Ltd (NYSE:RDY) announced its quarterly earnings results on Friday, October, 26th. The company reported $0.42 EPS for the quarter. The company earned $524 million during the quarter, compared to analyst estimates of $522.22 million. Dr.Reddy's Laboratories had a return on equity of 13.14% and a net margin of 10.62%. View Dr.Reddy's Laboratories' Earnings History.

When is Dr.Reddy's Laboratories' next earnings date?

Dr.Reddy's Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, January 24th 2019. View Earnings Estimates for Dr.Reddy's Laboratories.

Has Dr.Reddy's Laboratories been receiving favorable news coverage?

Media headlines about RDY stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Dr.Reddy's Laboratories earned a news impact score of 2.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near term.

Who are some of Dr.Reddy's Laboratories' key competitors?

Who are Dr.Reddy's Laboratories' key executives?

Dr.Reddy's Laboratories' management team includes the folowing people:
  • Mr. Gunupati Venkateswara Prasad, Co-Chairman, MD, CEO & Member of Management Council (Age 58)
  • Mr. Kallam Satish Reddy, Chairman & Member of the Management Council (Age 51)
  • Mr. Saumen Chakraborty, Pres, CFO, Global Head of IT & Bus. Process Excellence and Member of the Mgmt Council (Age 57)
  • Mr. M. V. Ramana, CEO & Head of Branded Markets - India & Emerging Countries and Member of Management Council (Age 49)
  • Mr. Ganadhish Kamat, Exec. VP, Global Head of Quality & Member of Management Council (Age 55)

Who are Dr.Reddy's Laboratories' major shareholders?

Dr.Reddy's Laboratories' stock is owned by a number of of retail and institutional investors. Top institutional investors include Commonwealth Bank of Australia (1.08%), BlackRock Inc. (1.05%), Vanguard Group Inc. (0.73%), Vanguard Group Inc (0.73%), Dimensional Fund Advisors LP (0.55%) and Renaissance Technologies LLC (0.47%).

Which institutional investors are selling Dr.Reddy's Laboratories stock?

RDY stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Jane Street Group LLC, JPMorgan Chase & Co., Mondrian Investment Partners LTD, First Trust Advisors LP, Prudential Financial Inc., Franklin Resources Inc. and Legal & General Group Plc.

Which institutional investors are buying Dr.Reddy's Laboratories stock?

RDY stock was acquired by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Renaissance Technologies LLC, BlackRock Inc., Sector Gamma AS, ClariVest Asset Management LLC, Dimensional Fund Advisors LP, GAM Holding AG and Nordea Investment Management AB.

How do I buy shares of Dr.Reddy's Laboratories?

Shares of RDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dr.Reddy's Laboratories' stock price today?

One share of RDY stock can currently be purchased for approximately $36.60.

How big of a company is Dr.Reddy's Laboratories?

Dr.Reddy's Laboratories has a market capitalization of $6.18 billion and generates $2.20 billion in revenue each year. The company earns $151 million in net income (profit) each year or $1.01 on an earnings per share basis. Dr.Reddy's Laboratories employs 23,524 workers across the globe.

What is Dr.Reddy's Laboratories' official website?

The official website for Dr.Reddy's Laboratories is http://www.drreddys.com.

How can I contact Dr.Reddy's Laboratories?

Dr.Reddy's Laboratories' mailing address is 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034. The company can be reached via phone at 91-40-4900-2900 or via email at [email protected]


MarketBeat Community Rating for Dr.Reddy's Laboratories (NYSE RDY)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  220 (Vote Outperform)
Underperform Votes:  299 (Vote Underperform)
Total Votes:  519
MarketBeat's community ratings are surveys of what our community members think about Dr.Reddy's Laboratories and other stocks. Vote "Outperform" if you believe RDY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel